By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a



Company News
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015 6:39:15 AM
BerGenBio AS Release: BGB324 And BGB10C9 Show Promise In Models Of Pancreatic Cancer 6/1/2015 7:51:18 AM
BerGenBio AS Completes NOK90 Million Fundraising 12/15/2014 7:47:21 AM
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014 11:31:38 AM
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014 7:41:49 AM
BerGenBio AS Granted A Prestigious Wellcome Trust Seeding Drug Discovery Award 9/23/2014 8:49:36 AM
BerGenBio AS Granted Platform Patent - Cellselect™ Platform Also Described In Peer-Reviewed Journal 9/8/2014 9:18:52 AM
BerGenBio AS Presents Positive Phase Ia Data On BGB324 At American Association for Cancer Research 4/9/2014 11:09:17 AM
BerGenBio AS Wraps Up $12.5 Million Funding Round 2/5/2014 5:34:39 AM
BerGenBio AS Presents Data At American Association for Cancer Research-ISLAC Conference On The Molecular Origins Of Lung Cancer 1/9/2014 10:34:31 AM